- Kidney Home
AlloSure is the first and only clinically and analytically validated, non-invasive donor-derived cell-free DNA (dd-cfDNA) test for identifying kidney injury. AlloSure can accurately determine active rejection, enabling better management of your kidney transplant patients.
The most comprehensive tool for transplant patient surveillance. KidneyCare combines clinically validated AlloSure test with research use only AlloMap Kidney and iBox, enabling you to follow trends and trajectory of kidney allograft health.
Drive better outcomes for Kidney transplant recipients
Better Surveillance. Better Outcomes.
AlloSure is the first non-invasive test that assesses organ health by directly measuring allograft injury, enabling better management of your kidney transplant recipients.
What is AlloSure?
AlloSure is a clinically and analytically validated, non-invasive donor-derived cell-free DNA (dd-cfDNA) test for identifying kidney injury.
WHAT IS CELL-FREE DNA (cfDNA)?
AlloSure is validated and reimbursable through Medicare
It’s time for innovation
THE LATEST INNOVATION IN KIDNEY TRANSPLANT SURVEILLANCE.
The most comprehensive tool for transplant patient surveillance.*
What is KidneyCare?
KidneyCare is the most comprehensive option for surveilling kidney allograft health, combining our clinically-validated AlloSure Kidney dd-cfDNA test, gene expression profiling with AlloMap Kidney, and predictive intelligence with iBox.
The Latest innovation in Kidney Transplant Surveillance can Drive Better Outcomes for your Patients.
Graft Survival Prognosis
*KidneyCare is available for research use only and not intended for diagnostic procedures.